TCA
NVCR icon

Transcend Capital Advisors’s NovoCure NVCR Stock Holding History

Transcend Capital Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78M Buy
117,221
+101,545
+648% +$1.54M 0.12% 162
2026
Q1 		$171K Buy
+15,676
New +$196K 0.01% 694

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Transcend Capital Advisors's NVCR Position: Q2 2026 in Review

Transcend Capital Advisors increased its NovoCure (NVCR) stake by 648% in Q2 2026, buying an estimated $1.54M and bringing the position to 117,221 shares worth $1.78M. The position accounts for 0.12% of the portfolio, ranked #162.

Transcend Capital Advisors first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Transcend Capital Advisors held 117,221 shares of NovoCure worth $1.78M as of Q2 2026.
  • Transcend Capital Advisors bought 101,545 NovoCure shares in Q2 2026, an estimated $1.54M.
  • NovoCure made up 0.12% of Transcend Capital Advisors's portfolio in Q2 2026, its #162 holding.
  • Transcend Capital Advisors first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.